CorpWatch : Gilead Sciences Under Investigation for Over-Charging for Hepatitis C Pill

July 21, 2014 2:23 PM

11 0

CorpWatch : Gilead Sciences Under Investigation for Over-Charging for Hepatitis C Pill

Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.

Sovaldi - the brand name for sofosbuvir - was approved last December by the U.S. Food and Drug Administration, to treat hepatitis C, a viral infection that can cause fever, fatigue, cirrhosis and deadly liver cancer. Some 150 million people around the world are estimated to be at risk, often many ye...

Also read: Trump likely to tap Tillerson for secretary of state

Read more

To category page

Loading...